Deciphering the radiobiology of targeted radionuclide therapy: from subcellular to intra-tumoural analyses

This project aims to enhance targeted radionuclide therapies for metastatic cancer by elucidating radiobiological mechanisms and developing advanced imaging techniques to improve treatment strategies.

Subsidie
€ 1.750.000
2022

Projectdetails

Background and Unmet Need

Targeted radionuclide therapies (TRTs) are a promising modality to treat patients with metastasized cancer. TRTs function via systemic administration of radiolabelled molecules (α- and β-particle emitters) designed to target tumour cells.

However, the radiobiological effects of TRTs are poorly understood, and rational design of new modalities based on underlying cellular mechanisms is therefore not possible, resulting in suboptimal treatment strategies. Since most patients with advanced cancer cannot be cured at the moment, it is therefore my ultimate goal to improve TRT.

Aim

My ERC project aims to identify and quantitate specific radiobiological mechanisms of TRT-radiation effects in vitro and in vivo.

Objectives

This unique multidisciplinary project will yield critical information on:

  1. Subcellular and intra-tumoural radiopharmaceutical uptake kinetics
  2. DNA damage response kinetics
  3. Dose response simulations

These objectives will profoundly increase our knowledge on TRT to push the field forward.

I will determine cellular dosimetric parameters for α-TRT and β-TRT, determine effects of subcellular and intra-tumoural localizations of TRT on DNA damage induction and survival, image in vivo TRT efficacy, and define effects of treatment heterogeneity to ultimately perform realistic dosimetric simulations in 2D and 3D cancer models.

Besides using previously developed techniques, we will develop an innovative new imaging setup for high-resolution imaging of TRT by intravital confocal microscopy to image real-time cellular processes of anti-cancer therapies in a living organism.

Expected Outcomes

The outcome of my project will not only increase our fundamental knowledge on TRT and yield a novel imaging modality, but additionally has high potential to contribute to improved treatment strategies and ultimately patient outcomes.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.750.000
Totale projectbegroting€ 1.750.000

Tijdlijn

Startdatum1-6-2022
Einddatum31-5-2027
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAMpenvoerder

Land(en)

Netherlands

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Capturing tumoral drug metabolism by Cells In the Tissue Environment using spatial pharmacometabolomics

The CITE project aims to develop innovative analytical technologies to study intratumoral drug metabolism in pancreatic cancer, enhancing understanding of treatment resistance mechanisms.

€ 2.481.640
ERC Advanced...

From understanding to rational design of next-generation cancer therapies

The project aims to enhance cancer treatment efficacy by combining immunotherapy with ultra-low dose therapies to exploit sublethal damage in tumor cells, improving tolerability and clinical outcomes.

€ 2.499.893
ERC Consolid...

Deciphering non-genetic determinants and targetability of cancer cell plasticity.

This project aims to reverse cancer cell plasticity in pediatric tumors using advanced genomic techniques to develop new therapeutic strategies for effective treatment.

€ 2.000.000
ERC Starting...

Targeting SWI/SNF-related chromatin remodelling defects in solid tumours

This project aims to uncover and exploit synthetic lethal vulnerabilities in SWI/SNF-deficient tumours to enhance anti-tumour immune responses and develop novel immuno-oncology therapies.

€ 1.499.887
ERC Starting...

Decoding Requirements for Infiltration of T ceLLs into solid tumors

This project aims to enhance T cell infiltration into pancreatic cancer by investigating chemokine regulation and T cell determinants, potentially improving immunotherapy efficacy.

€ 1.521.000

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

Live Cell Spectroscopy Analysis for Personalised Particle Radiation Therapy of Metastatic Bone Cancer

BoneOscopy aims to revolutionize metastatic bone cancer treatment by enabling daily monitoring during particle radiotherapy, enhancing personalized care and treatment efficacy.

€ 3.069.321
EIC Pathfinder

Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.

NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.

€ 5.972.875
EIC Pathfinder

2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography Approach

PERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects.

€ 2.740.675
EIC Pathfinder

SUPRAMOLECULAR AGENTS AS RADIOTHERANOSTIC DRUGS

SMARTdrugs aims to revolutionize cancer treatment by developing supramolecular radiotheranostics that integrate diagnostics and therapy for targeted drug delivery.

€ 2.135.087
EIC Pathfinder

NEXT GENERATION IMAGING FOR REAL-TIME DOSE VERIFICATION ENABLING ADAPTIVE PROTON THERAPY

The NOVO project aims to develop a groundbreaking real-time dose verification technology for proton radiotherapy, enhancing personalized cancer treatment and improving patient outcomes.

€ 3.759.489